ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +25.00%. A quarter ago, it was expected that this immunotherapy company would post a loss of $0.1 per share when it actually produced a loss of $0.07, delivering a surprise of +30%.Over the last four quarters, the company ha ...